Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company's pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London, United Kingdom.
| Revenue (Most Recent Fiscal Year) | $75.39M |
| Net Income (Most Recent Fiscal Year) | $-287.53M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 4.98 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.11 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -378.78% |
| Net Margin (Trailing 12 Months) | -381.40% |
| Return on Equity (Trailing 12 Months) | -99.05% |
| Return on Assets (Trailing 12 Months) | -42.31% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.94 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.86 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 3.87 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.61 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.34 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.08 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.08 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 266.14M |
| Free Float | 197.74M |
| Market Capitalization | $375.26M |
| Average Volume (Last 20 Days) | 1.83M |
| Beta (Past 60 Months) | 2.04 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 25.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 72.83% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |